{"id":55569,"date":"2023-04-06T07:03:35","date_gmt":"2023-04-06T05:03:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\/"},"modified":"2023-04-06T07:03:35","modified_gmt":"2023-04-06T05:03:35","slug":"innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\/","title":{"rendered":"Innate Pharma Files Its 2022 Universal Registration Document (Document d\u2019enregistrement universel) and 2022 Annual Report on Form 20-F"},"content":{"rendered":"
\n

MARSEILLE, France–(BUSINESS WIRE)–#ANKET<\/a>–Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate<\/b>\u201d or the \u201cCompany<\/b>\u201d) today announced the filing of its 2022 Universal Registration Document (Document d\u2019enregistrement universel<\/i>) for the year ending December 31, 2022 with the French market authority \u201cAutorit\u00e9 des March\u00e9s Financiers\u201d (\u201cAMF<\/b>\u201d) on April 6, 2023. It can be downloaded (in French) on the Company\u2019s website<\/a> and on the AMF\u2019s website<\/a>.<\/p>\n

<\/a><\/p>\n

\nThe Company also announced today the filing of its annual report on Form 20-F for the year ending December 31, 2022 with the United States Securities and Exchange Commission (\u201cSEC<\/b>\u201d). It can be also be accessed on the Company\u2019s website<\/a> and on the SEC\u2019s website<\/a>.<\/p>\n

\nAbout Innate Pharma<\/b><\/p>\n

\nInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET\u00ae<\/sup> (A<\/b>ntibody-based NK<\/b> cell E<\/b>ngager T<\/b>herapeutics) proprietary platform.<\/p>\n

\nInnate\u2019s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET\u00ae<\/sup> multi-specific NK cell engagers to address multiple tumor types.<\/p>\n

\nInnate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.<\/p>\n

\nHeadquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.<\/p>\n

\nLearn more about Innate Pharma at www.innate-pharma.com<\/a> and follow us on Twitter<\/a> and LinkedIn<\/a>.<\/p>\n

\nInformation about Innate Pharma shares<\/b><\/p>\n\n\n
\n

\nISIN code<\/b>
Ticker code<\/b>
LEI<\/b><\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nFR0010331421<\/p>\n

\nEuronext: IPH Nasdaq: IPHA<\/p>\n

\n9695002Y8420ZB8HJE29<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

<\/div>\n

\nDisclaimer on forward-looking information and risk factors<\/b><\/p>\n

\nThis press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including \u201cbelieve,\u201d \u201cpotential,\u201d \u201cexpect\u201d and \u201cwill\u201d and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company\u2019s commercialization efforts and the Company\u2019s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website http:\/\/www.amf-france.org<\/a> or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2022, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.<\/p>\n

\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors<\/span><\/b><\/p>\n

\nInnate Pharma<\/b>
Henry Wheeler
\n
Tel.: +33 (0)4 84 90 32 88
\n
Henry.wheeler@innate-pharma.fr<\/a><\/p>\n

\nMedia Relations<\/span><\/b><\/p>\n

\nNewCap<\/b>
Arthur Rouill\u00e9
\n
Tel.: +33 (0)1 44 71 00 15
\n
innate@newcap.eu<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MARSEILLE, France–(BUSINESS WIRE)–#ANKET–Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced the filing of its 2022 Universal Registration Document (Document d\u2019enregistrement universel) for the year ending December 31, 2022 with the French market authority \u201cAutorit\u00e9 des March\u00e9s Financiers\u201d (\u201cAMF\u201d) on April 6, 2023. It can be downloaded (in French) on … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55569","6":"format-standard","7":"category-industry"},"yoast_head":"\nInnate Pharma Files Its 2022 Universal Registration Document (Document d\u2019enregistrement universel) and 2022 Annual Report on Form 20-F - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate Pharma Files Its 2022 Universal Registration Document (Document d\u2019enregistrement universel) and 2022 Annual Report on Form 20-F - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MARSEILLE, France–(BUSINESS WIRE)–#ANKET–Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced the filing of its 2022 Universal Registration Document (Document d\u2019enregistrement universel) for the year ending December 31, 2022 with the French market authority \u201cAutorit\u00e9 des March\u00e9s Financiers\u201d (\u201cAMF\u201d) on April 6, 2023. It can be downloaded (in French) on ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-06T05:03:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230405005495\/en\/1245155\/21\/INNATEvertnoirDS.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Innate Pharma Files Its 2022 Universal Registration Document (Document d\u2019enregistrement universel) and 2022 Annual Report on Form 20-F\",\"datePublished\":\"2023-04-06T05:03:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\\\/\"},\"wordCount\":610,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230405005495\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\\\/\",\"name\":\"Innate Pharma Files Its 2022 Universal Registration Document (Document d\u2019enregistrement universel) and 2022 Annual Report on Form 20-F - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230405005495\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"datePublished\":\"2023-04-06T05:03:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230405005495\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230405005495\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innate Pharma Files Its 2022 Universal Registration Document (Document d\u2019enregistrement universel) and 2022 Annual Report on Form 20-F\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innate Pharma Files Its 2022 Universal Registration Document (Document d\u2019enregistrement universel) and 2022 Annual Report on Form 20-F - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\/","og_locale":"en_US","og_type":"article","og_title":"Innate Pharma Files Its 2022 Universal Registration Document (Document d\u2019enregistrement universel) and 2022 Annual Report on Form 20-F - Pharma Trend","og_description":"MARSEILLE, France–(BUSINESS WIRE)–#ANKET–Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced the filing of its 2022 Universal Registration Document (Document d\u2019enregistrement universel) for the year ending December 31, 2022 with the French market authority \u201cAutorit\u00e9 des March\u00e9s Financiers\u201d (\u201cAMF\u201d) on April 6, 2023. It can be downloaded (in French) on ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-06T05:03:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230405005495\/en\/1245155\/21\/INNATEvertnoirDS.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Innate Pharma Files Its 2022 Universal Registration Document (Document d\u2019enregistrement universel) and 2022 Annual Report on Form 20-F","datePublished":"2023-04-06T05:03:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\/"},"wordCount":610,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230405005495\/en\/1245155\/21\/INNATEvertnoirDS.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\/","url":"https:\/\/pharma-trend.com\/en\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\/","name":"Innate Pharma Files Its 2022 Universal Registration Document (Document d\u2019enregistrement universel) and 2022 Annual Report on Form 20-F - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230405005495\/en\/1245155\/21\/INNATEvertnoirDS.jpg","datePublished":"2023-04-06T05:03:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230405005495\/en\/1245155\/21\/INNATEvertnoirDS.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230405005495\/en\/1245155\/21\/INNATEvertnoirDS.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-files-its-2022-universal-registration-document-document-denregistrement-universel-and-2022-annual-report-on-form-20-f\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Innate Pharma Files Its 2022 Universal Registration Document (Document d\u2019enregistrement universel) and 2022 Annual Report on Form 20-F"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55569"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55569\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}